JP2015515992A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015515992A5 JP2015515992A5 JP2015510507A JP2015510507A JP2015515992A5 JP 2015515992 A5 JP2015515992 A5 JP 2015515992A5 JP 2015510507 A JP2015510507 A JP 2015510507A JP 2015510507 A JP2015510507 A JP 2015510507A JP 2015515992 A5 JP2015515992 A5 JP 2015515992A5
- Authority
- JP
- Japan
- Prior art keywords
- particle
- mol
- peg
- lipids
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002245 particle Substances 0.000 claims description 48
- 150000002632 lipids Chemical class 0.000 claims description 18
- 150000003904 phospholipids Chemical class 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 229940124597 therapeutic agent Drugs 0.000 claims description 8
- 229940039227 diagnostic agent Drugs 0.000 claims description 6
- 239000000032 diagnostic agent Substances 0.000 claims description 6
- 239000002502 liposome Substances 0.000 claims description 6
- 239000002105 nanoparticle Substances 0.000 claims description 6
- 230000000069 prophylactic effect Effects 0.000 claims description 6
- 239000003381 stabilizer Substances 0.000 claims description 6
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 4
- 230000005494 condensation Effects 0.000 claims description 4
- 238000009833 condensation Methods 0.000 claims description 4
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 4
- 229930182558 Sterol Natural products 0.000 claims description 2
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical group O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 claims description 2
- 235000012000 cholesterol Nutrition 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 229960004679 doxorubicin Drugs 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 150000002313 glycerolipids Chemical class 0.000 claims description 2
- 150000002327 glycerophospholipids Chemical class 0.000 claims description 2
- 239000012216 imaging agent Substances 0.000 claims description 2
- 229930001119 polyketide Natural products 0.000 claims description 2
- 125000000830 polyketide group Chemical group 0.000 claims description 2
- 150000003135 prenol lipids Chemical class 0.000 claims description 2
- 150000003313 saccharo lipids Chemical class 0.000 claims description 2
- 150000003408 sphingolipids Chemical class 0.000 claims description 2
- -1 sterol lipids Chemical class 0.000 claims description 2
- 235000003702 sterols Nutrition 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 1
- 210000003097 mucus Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261642776P | 2012-05-04 | 2012-05-04 | |
| US61/642,776 | 2012-05-04 | ||
| PCT/US2013/039731 WO2013166498A1 (en) | 2012-05-04 | 2013-05-06 | Lipid-based drug carriers for rapid penetration through mucus linings |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017220782A Division JP2018039836A (ja) | 2012-05-04 | 2017-11-16 | 粘液内層を通過する迅速な透過のための脂質ベース薬物キャリア |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015515992A JP2015515992A (ja) | 2015-06-04 |
| JP2015515992A5 true JP2015515992A5 (enExample) | 2016-06-23 |
| JP6392209B2 JP6392209B2 (ja) | 2018-09-19 |
Family
ID=48428718
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015510507A Active JP6392209B2 (ja) | 2012-05-04 | 2013-05-06 | 粘液内層を通過する迅速な透過のための脂質ベース薬物キャリア |
| JP2017220782A Withdrawn JP2018039836A (ja) | 2012-05-04 | 2017-11-16 | 粘液内層を通過する迅速な透過のための脂質ベース薬物キャリア |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017220782A Withdrawn JP2018039836A (ja) | 2012-05-04 | 2017-11-16 | 粘液内層を通過する迅速な透過のための脂質ベース薬物キャリア |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US9889208B2 (enExample) |
| EP (1) | EP2849728A1 (enExample) |
| JP (2) | JP6392209B2 (enExample) |
| AU (1) | AU2013256008B2 (enExample) |
| CA (1) | CA2872519C (enExample) |
| HK (1) | HK1208377A1 (enExample) |
| WO (1) | WO2013166498A1 (enExample) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005072710A2 (en) * | 2004-01-28 | 2005-08-11 | Johns Hopkins University | Drugs and gene carrier particles that rapidly move through mucous barriers |
| US8889193B2 (en) | 2010-02-25 | 2014-11-18 | The Johns Hopkins University | Sustained delivery of therapeutic agents to an eye compartment |
| EP3578205A1 (en) | 2010-08-06 | 2019-12-11 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
| WO2012039979A2 (en) | 2010-09-10 | 2012-03-29 | The Johns Hopkins University | Rapid diffusion of large polymeric nanoparticles in the mammalian brain |
| HUE069586T2 (hu) | 2010-10-01 | 2025-03-28 | Modernatx Inc | Módosított nukleozidok, nukleotidok és nukleinsavak, valamint ezek felhasználása |
| US9327037B2 (en) | 2011-02-08 | 2016-05-03 | The Johns Hopkins University | Mucus penetrating gene carriers |
| JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| DK3682905T3 (da) | 2011-10-03 | 2022-02-28 | Modernatx Inc | Modificerede nukleosider, nukleotider og nukleinsyrer og anvendelser deraf |
| HRP20220717T1 (hr) | 2011-12-16 | 2022-07-22 | Modernatx, Inc. | Modificirani pripravci mrna |
| EA032552B1 (ru) | 2012-03-16 | 2019-06-28 | Дзе Джонс Хопкинс Юниверсити | Препараты с контролируемым высвобождением для доставки ингибиторов hif-1 |
| AU2013232300B2 (en) | 2012-03-16 | 2015-12-17 | The Johns Hopkins University | Non-linear multiblock copolymer-drug conjugates for the delivery of active agents |
| JP6189415B2 (ja) | 2012-04-02 | 2017-08-30 | モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． | 細胞質および細胞骨格タンパク質の産生のための修飾ポリヌクレオチド |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| US9827191B2 (en) | 2012-05-03 | 2017-11-28 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| KR102310775B1 (ko) | 2012-05-03 | 2021-10-07 | 칼라 파마슈티컬스, 인크. | 개선된 점막 수송을 나타내는 제약 나노입자 |
| US10688041B2 (en) | 2012-05-03 | 2020-06-23 | Kala Pharmaceuticals, Inc. | Compositions and methods utilizing poly(vinyl alcohol) and/or other polymers that aid particle transport in mucus |
| US11596599B2 (en) | 2012-05-03 | 2023-03-07 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| JP6392209B2 (ja) | 2012-05-04 | 2018-09-19 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 粘液内層を通過する迅速な透過のための脂質ベース薬物キャリア |
| EP2922554B1 (en) | 2012-11-26 | 2022-02-23 | ModernaTX, Inc. | Terminally modified rna |
| WO2014124006A1 (en) | 2013-02-05 | 2014-08-14 | The Johns Hopkins University | Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof |
| EP2971010B1 (en) | 2013-03-14 | 2020-06-10 | ModernaTX, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| EP3052106A4 (en) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucleotides encoding immune modulating polypeptides |
| KR20160067219A (ko) | 2013-10-03 | 2016-06-13 | 모더나 세라퓨틱스, 인코포레이티드 | 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드 |
| US10335500B2 (en) | 2014-05-12 | 2019-07-02 | The Johns Hopkins University | Highly stable biodegradable gene vector platforms for overcoming biological barriers |
| CN107278151A (zh) | 2014-12-15 | 2017-10-20 | 约翰霍普金斯大学 | 舒尼替尼制剂及其在治疗青光眼中的使用方法 |
| CN107635545A (zh) | 2015-01-27 | 2018-01-26 | 约翰霍普金斯大学 | 用于增强粘膜表面处活性剂的输送的低渗水凝胶制剂 |
| WO2016203392A1 (en) * | 2015-06-15 | 2016-12-22 | Gexnano S.R.L. | Food supplement for use in a process of metabolic rebalancing |
| ES2908479T3 (es) | 2015-08-26 | 2022-04-29 | Achillion Pharmaceuticals Inc | Compuestos para el tratamiento de trastornos inmunitarios e inflamatorios |
| AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
| CN108289845A (zh) | 2015-09-14 | 2018-07-17 | 维吉思康科技公司 | 皮下、舌下和口服治疗用空间稳定载体、用于治疗哺乳动物的组合物和方法 |
| ES2969082T3 (es) | 2015-09-17 | 2024-05-16 | Modernatx Inc | Compuestos y composiciones para la administración intracelular de agentes terapéuticos |
| KR20180058758A (ko) | 2015-09-22 | 2018-06-01 | 그레이버그 비젼, 인크. | 안구 장애의 치료를 위한 화합물 및 조성물 |
| AU2016343840A1 (en) * | 2015-10-30 | 2018-06-07 | The Johns Hopkins University | Mucus penetrating particles with high molecular weight and dense coatings |
| BR112018009644A2 (pt) | 2015-11-12 | 2018-11-06 | Graybug Vision Inc | micropartículas agregantes sólidas modificadas na superfície, material injetável, processo para preparação de micropartículas agregantes sólidas modificadas na superfície, método para tratamento de um distúrbio ocular, e, uso de micropartículas agregantes sólidas modificadas na superfície |
| US10905783B2 (en) * | 2015-11-27 | 2021-02-02 | Michal RIVLIN | Glucosamine and derivatives thereof in imaging |
| PT3386484T (pt) | 2015-12-10 | 2022-08-01 | Modernatx Inc | Composições e métodos para entrega de agentes terapêuticos |
| US10799463B2 (en) | 2015-12-22 | 2020-10-13 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
| US10901058B2 (en) * | 2016-02-05 | 2021-01-26 | The Trustees Of The University Of Pennsylvania | Chemical exchange saturation transfer (CEST) imaging of lactate (LATEST) |
| WO2017136700A1 (en) | 2016-02-05 | 2017-08-10 | The Trustees Of The University Of Pennsylvania | Non-nutritive sweeteners and polyols as imaging agents |
| WO2017153993A1 (en) * | 2016-03-09 | 2017-09-14 | Technion Research And Development Foundation Ltd. | Liposomal formulations and methods of using same in agriculture |
| MX2018016046A (es) | 2016-06-27 | 2019-05-02 | Achillion Pharmaceuticals Inc | Quinazolina y compuestos indol para tratar trastornos medicos. |
| US10842746B1 (en) * | 2016-08-25 | 2020-11-24 | Verily Life Sciences Llc | Bi-directionally crosslinked liposomes and method of making same |
| WO2018089540A1 (en) | 2016-11-08 | 2018-05-17 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| CA3053818A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders |
| AU2018234814B2 (en) | 2017-03-15 | 2022-06-30 | Modernatx, Inc. | Crystal forms of amino lipids |
| ES3020935T3 (en) | 2017-03-15 | 2025-05-23 | Modernatx Inc | Lipid nanoparticle formulation |
| ES2940259T3 (es) | 2017-03-15 | 2023-05-04 | Modernatx Inc | Compuesto y composiciones para la administración intracelular de agentes terapéuticos |
| JP7217022B2 (ja) | 2017-03-23 | 2023-02-02 | グレイバグ ビジョン インコーポレイテッド | 眼障害の治療のための薬物及び組成物 |
| CA3057875A1 (en) | 2017-05-10 | 2018-11-15 | Graybug Vision, Inc. | Extended release microparticles and suspensions thereof for medical therapy |
| EP3638678B1 (en) | 2017-06-14 | 2025-12-03 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of agents |
| US11786607B2 (en) | 2017-06-15 | 2023-10-17 | Modernatx, Inc. | RNA formulations |
| JP7275111B2 (ja) | 2017-08-31 | 2023-05-17 | モデルナティエックス インコーポレイテッド | 脂質ナノ粒子の生成方法 |
| CA3085694A1 (en) | 2017-12-12 | 2019-06-20 | Lead Biotherapeutics Ltd. | Solid lipid nanoparticle for intracellular release of active substances and method for production the same |
| JP7538113B2 (ja) | 2018-08-20 | 2024-08-21 | アキリオン ファーマシューティカルズ，インコーポレーテッド | 補体ｄ因子の医学的障害の治療のための医薬化合物 |
| US11814391B2 (en) | 2018-09-06 | 2023-11-14 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for the treatment of medical disorders |
| TWI755629B (zh) * | 2018-09-13 | 2022-02-21 | 台灣微脂體股份有限公司 | 含鎮靜藥物之緩釋藥物組合物及其用途 |
| EP4509118A3 (en) | 2018-09-19 | 2025-05-14 | ModernaTX, Inc. | High-purity peg lipids and uses thereof |
| JP7410135B2 (ja) | 2018-09-19 | 2024-01-09 | モデルナティエックス インコーポレイテッド | 治療薬の細胞内送達のための化合物及び組成物 |
| JP7526168B2 (ja) | 2018-09-19 | 2024-07-31 | モデルナティエックス インコーポレイテッド | Ｐｅｇ脂質及びそれらの使用 |
| WO2020061457A1 (en) | 2018-09-20 | 2020-03-26 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| JP7504088B2 (ja) | 2018-10-16 | 2024-06-21 | ジョージア ステイト ユニバーシティー リサーチ ファウンデーション インコーポレイテッド | 医学的障害の治療のための一酸化炭素プロドラッグ |
| WO2020210805A1 (en) | 2019-04-11 | 2020-10-15 | The Johns Hopkins University | Nanoparticles for drug delivery to brain |
| CA3154618A1 (en) | 2019-09-19 | 2021-03-25 | Modernatx, Inc. | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents |
| JP2023515073A (ja) | 2020-02-20 | 2023-04-12 | アキリオン ファーマシューティカルズ， インコーポレーテッド | 補体因子ｄ媒介障害の処置用のヘテロアリール化合物 |
| JP7787164B2 (ja) | 2020-09-23 | 2025-12-16 | アキリオン ファーマシューティカルズ， インコーポレーテッド | 補体媒介性障害の治療のための医薬化合物 |
| US11058637B1 (en) * | 2020-11-25 | 2021-07-13 | King Abdulaziz University | Surface-modified emulsomes for intranasal delivery of drugs |
| US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
| WO2022235907A1 (en) * | 2021-05-05 | 2022-11-10 | Vgsk Technologies, Inc. | Liposome-encapsulated corticosteriods inhibit sars-cov-2 replication and reduces lung inflammation |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2026989A (en) | 1931-08-12 | 1936-01-07 | T R C Corp | Method of building roads |
| US2005204A (en) | 1933-02-23 | 1935-06-18 | Ralph R Poynter | Lawn mower |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US4997652A (en) | 1987-12-22 | 1991-03-05 | Visionex | Biodegradable ocular implants |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5356633A (en) * | 1989-10-20 | 1994-10-18 | Liposome Technology, Inc. | Method of treatment of inflamed tissues |
| US5196522A (en) | 1990-11-01 | 1993-03-23 | Board Of Regents, The University Of Texas System | Anthracycline analogues bearing latent alkylating substituents |
| US5696298A (en) | 1991-03-19 | 1997-12-09 | Cytrx Corporation | Polyoxypropylene/polyoxyethylene copolymers with improved biological activity |
| EP0627911B1 (en) | 1992-02-28 | 2000-10-25 | Board Of Regents The University Of Texas System | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers |
| US5565215A (en) | 1993-07-23 | 1996-10-15 | Massachusettes Institute Of Technology | Biodegradable injectable particles for imaging |
| US5540930A (en) | 1993-10-25 | 1996-07-30 | Pharmos Corporation | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
| US6007845A (en) | 1994-07-22 | 1999-12-28 | Massachusetts Institute Of Technology | Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers |
| US5576311A (en) | 1994-11-30 | 1996-11-19 | Pharmos Corporation | Cyclodextrins as suspending agents for pharmaceutical suspensions |
| US5628981A (en) | 1994-12-30 | 1997-05-13 | Nano Systems L.L.C. | Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US6413539B1 (en) | 1996-10-31 | 2002-07-02 | Poly-Med, Inc. | Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof |
| PT751144E (pt) | 1995-06-27 | 2004-12-31 | Pharmachemie Bv | Novos pro-farmacos antraciclinicos, metodo para preparacao e tambem a sua utilizacao em quimioterapia selectiva |
| NZ332578A (en) | 1996-05-09 | 2000-06-23 | Infectio Recherche Inc | Gel formulation containing poloxamer compound for use in the prevention of pathogen induced diseases including HIV and HSV |
| US5869130A (en) | 1997-06-12 | 1999-02-09 | Mac Dermid, Incorporated | Process for improving the adhesion of polymeric materials to metal surfaces |
| US7052678B2 (en) | 1997-09-15 | 2006-05-30 | Massachusetts Institute Of Technology | Particles for inhalation having sustained release properties |
| US6270806B1 (en) | 1999-03-03 | 2001-08-07 | Elan Pharma International Limited | Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions |
| US6963769B1 (en) | 1999-04-21 | 2005-11-08 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method for enhancing contrast produced by MRI |
| US6287588B1 (en) | 1999-04-29 | 2001-09-11 | Macromed, Inc. | Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof |
| DE60014818T2 (de) | 1999-10-01 | 2006-03-09 | Toda Kogyo Corp. | Auf Mg-Al basierende Hydrotalcitteilchen, Stabilisator für chlorhaltige Harze und Verfahren zur Herstellung der Teilchen |
| AU2136501A (en) * | 1999-12-10 | 2001-06-18 | Celator Technologies Inc. | Lipid carrier compositions with protected surface reactive functions |
| US6589549B2 (en) | 2000-04-27 | 2003-07-08 | Macromed, Incorporated | Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles |
| US6495164B1 (en) | 2000-05-25 | 2002-12-17 | Alkermes Controlled Therapeutics, Inc. I | Preparation of injectable suspensions having improved injectability |
| PE20020146A1 (es) | 2000-07-13 | 2002-03-31 | Upjohn Co | Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2) |
| CN101584867A (zh) | 2000-10-31 | 2009-11-25 | 瑟莫迪克斯药品公司 | 提高生物活性分子传递的方法和组合物 |
| GB0122318D0 (en) | 2001-09-14 | 2001-11-07 | Novartis Ag | Organic compounds |
| US7381426B2 (en) * | 2002-01-24 | 2008-06-03 | Southwest Research Institute | Targeted delivery of bioactive factors to the systemic skeleton |
| US7901708B2 (en) * | 2002-06-28 | 2011-03-08 | Protiva Biotherapeutics, Inc. | Liposomal apparatus and manufacturing methods |
| CA2508015C (en) | 2002-12-30 | 2012-04-03 | Nektar Therapeutics Al, Corporation | Multi-arm polypeptide-poly(ethylene glycol) block copolymers as drug delivery vehicles |
| US20050009910A1 (en) | 2003-07-10 | 2005-01-13 | Allergan, Inc. | Delivery of an active drug to the posterior part of the eye via subconjunctival or periocular delivery of a prodrug |
| US7696359B2 (en) * | 2003-09-03 | 2010-04-13 | Kyowa Hakko Kirin Co., Ltd. | Compound modified with glycerol derivative |
| GB0328630D0 (en) | 2003-12-10 | 2004-01-14 | Medpharm Ltd | Metered dose inhalation preparations |
| WO2005065657A2 (en) | 2003-12-31 | 2005-07-21 | Pfizer Products Inc. | Solid compositions of low-solubility drugs and poloxamers |
| WO2005072710A2 (en) | 2004-01-28 | 2005-08-11 | Johns Hopkins University | Drugs and gene carrier particles that rapidly move through mucous barriers |
| CN101052644A (zh) | 2004-02-05 | 2007-10-10 | 因特拉迪格姆公司 | 治疗眼新生血管化疾病的RNAi治疗药物 |
| ES2246694B1 (es) | 2004-04-29 | 2007-05-01 | Instituto Cientifico Y Tecnologico De Navarra, S.A. | Nanoparticulas pegiladas. |
| BRPI0510485A (pt) | 2004-04-30 | 2007-11-13 | Allergan Inc | implantes inibidores de tirosina cinase intravìtreos biodegradáveis |
| US7771742B2 (en) | 2004-04-30 | 2010-08-10 | Allergan, Inc. | Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods |
| US20050244469A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
| US8354476B2 (en) | 2004-12-10 | 2013-01-15 | Kala Pharmaceuticals, Inc. | Functionalized poly(ether-anhydride) block copolymers |
| JP2008536944A (ja) | 2005-04-22 | 2008-09-11 | アルザ・コーポレーシヨン | Ｈｅｒ２細胞受容体を標的とするためのイムノリポソーム組成物 |
| JP2006335745A (ja) * | 2005-06-06 | 2006-12-14 | Fujifilm Holdings Corp | リポソームを含むｍｒｉ造影剤 |
| EP1912676A2 (en) | 2005-07-28 | 2008-04-23 | (Osi) Eyetech, Inc. | Cyclitol linker polymer conjugate |
| US20070071756A1 (en) | 2005-09-26 | 2007-03-29 | Peyman Gholam A | Delivery of an agent to ameliorate inflammation |
| US20070093461A1 (en) | 2005-10-26 | 2007-04-26 | Bausch & Lomb Incorporated | Effect of Loteprednol etabonate on vascular dysfunction |
| US8658608B2 (en) | 2005-11-23 | 2014-02-25 | Yale University | Modified triple-helix forming oligonucleotides for targeted mutagenesis |
| EP1962803A1 (en) | 2005-12-23 | 2008-09-03 | Alcon, Inc. | PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE |
| US8663674B2 (en) | 2006-01-13 | 2014-03-04 | Surmodics, Inc. | Microparticle containing matrices for drug delivery |
| US20070231360A1 (en) | 2006-03-28 | 2007-10-04 | Minu, L.L.C. | Neural conduit agent dissemination |
| US20080166411A1 (en) | 2006-04-10 | 2008-07-10 | Pfizer Inc | Injectable Depot Formulations And Methods For Providing Sustained Release Of Poorly Soluble Drugs Comprising Nanoparticles |
| US20070249536A1 (en) | 2006-04-25 | 2007-10-25 | Ma Peter X | Three-component polyanhydride copolymers and a method of forming the same |
| US8858989B2 (en) * | 2006-05-18 | 2014-10-14 | Biolitec Pharma Marketing Ltd | Gel-formulations of hydrophobic photosensitizers for mucosal applications |
| JP2008053276A (ja) | 2006-08-22 | 2008-03-06 | Nec Electronics Corp | 半導体装置の製造方法 |
| AU2007292902B8 (en) | 2006-09-08 | 2013-09-05 | Johns Hopkins University | Compositions and methods for enhancing transport through mucus |
| US8394488B2 (en) | 2006-10-06 | 2013-03-12 | Cordis Corporation | Bioabsorbable device having composite structure for accelerating degradation |
| AR063621A1 (es) | 2006-11-09 | 2009-02-04 | Alcon Res Ltd | Matriz polimerica insoluble en agua para la administracion de farmacos |
| US20080213352A1 (en) * | 2007-03-02 | 2008-09-04 | Luna Innovations Incorporated | Liposome carriers for in vivo delivery of fullerenes |
| BRPI0819081A8 (pt) | 2007-10-08 | 2016-08-30 | Fovea Pharmaceuticals Sa | Formulação oftálmica aquosa, processo para preparar a mesma, e, método para inibir, tratar ou prevenir doenças oculares e doença ou condição relacionada, em um paciente em necessidade de tal tratamento |
| JP2009096749A (ja) * | 2007-10-16 | 2009-05-07 | Konica Minolta Holdings Inc | コレステロール誘導体、リポソーム及びｘ線用造影剤 |
| WO2009100176A2 (en) | 2008-02-07 | 2009-08-13 | Abbott Laboratories | Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor |
| WO2010030739A1 (en) * | 2008-09-10 | 2010-03-18 | Abbott Laboratories | Polyethylene glycol lipid conjugates and uses thereof |
| MY155629A (en) | 2008-10-10 | 2015-11-13 | Polyactiva Pty Ltd | Biodegradable polymer-bioactive moiety conjugates |
| US20120052041A1 (en) | 2009-02-04 | 2012-03-01 | The Brigham And Women's Hospital, Inc. | Polymeric nanoparticles with enhanced drug-loading and methods of use thereof |
| ES2508290T3 (es) | 2009-03-03 | 2014-10-16 | Alcon Research, Ltd. | Composición farmacéutica para la administracón de compuestos de inhibición del receptor de tirosina cinasa (RTKI) al ojo |
| US10952965B2 (en) | 2009-05-15 | 2021-03-23 | Baxter International Inc. | Compositions and methods for drug delivery |
| WO2010143969A2 (en) | 2009-06-08 | 2010-12-16 | Epitarget As | Acoustically sensitive drug delivery particles comprising non-lamellar forming phosphatidylethanolamine |
| EP2335686A1 (en) | 2009-12-21 | 2011-06-22 | LEK Pharmaceuticals d.d. | An aqueous intravenous nanosuspension with reduced adverse effects |
| US8889193B2 (en) | 2010-02-25 | 2014-11-18 | The Johns Hopkins University | Sustained delivery of therapeutic agents to an eye compartment |
| US20130071349A1 (en) | 2010-03-02 | 2013-03-21 | Allergan, Inc. | Biodegradable polymers for lowering intraocular pressure |
| US20110262406A1 (en) | 2010-04-21 | 2011-10-27 | Yale University | Compositions and methods for targeted inactivation of hiv cell surface receptors |
| EP2407157A1 (en) * | 2010-07-13 | 2012-01-18 | Koninklijke Philips Electronics N.V. | Lipid bilayer carrier for drugs or imaging agents |
| WO2012039979A2 (en) | 2010-09-10 | 2012-03-29 | The Johns Hopkins University | Rapid diffusion of large polymeric nanoparticles in the mammalian brain |
| EP2635254B1 (en) | 2010-11-05 | 2019-05-15 | The John Hopkins University | Compositions and methods relating to reduced mucoadhesion |
| US9327037B2 (en) | 2011-02-08 | 2016-05-03 | The Johns Hopkins University | Mucus penetrating gene carriers |
| CN102379850B (zh) * | 2011-11-04 | 2013-08-28 | 北京泰德制药股份有限公司 | 一种穿越人体粘液屏障的靶向给药脂质体 |
| AU2012351994B2 (en) | 2011-12-14 | 2015-11-05 | The Johns Hopkins University | Nanoparticles with enhanced mucosal penetration or decreased inflammation |
| US20130217657A1 (en) | 2011-12-21 | 2013-08-22 | Insite Vision Incorporated | Combination anti-inflammatory ophthalmic compositions |
| AU2013209452B2 (en) | 2012-01-19 | 2015-11-05 | The Johns Hopkins University | Nanoparticle formulations with enhanced mucosal penetration |
| EP2819652A1 (en) * | 2012-02-27 | 2015-01-07 | Epitarget As | Use of a particulate immunomodulator in cancer therapy |
| EA032552B1 (ru) | 2012-03-16 | 2019-06-28 | Дзе Джонс Хопкинс Юниверсити | Препараты с контролируемым высвобождением для доставки ингибиторов hif-1 |
| AU2013232300B2 (en) | 2012-03-16 | 2015-12-17 | The Johns Hopkins University | Non-linear multiblock copolymer-drug conjugates for the delivery of active agents |
| US20140107025A1 (en) | 2012-04-16 | 2014-04-17 | Jade Therapeutics, Llc | Ocular drug delivery system |
| US9827191B2 (en) | 2012-05-03 | 2017-11-28 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| KR102310775B1 (ko) | 2012-05-03 | 2021-10-07 | 칼라 파마슈티컬스, 인크. | 개선된 점막 수송을 나타내는 제약 나노입자 |
| NZ741873A (en) | 2012-05-03 | 2019-04-26 | Kala Pharmaceuticals Inc | Pharmaceutical nanoparticles showing improved mucosal transport |
| US10688041B2 (en) | 2012-05-03 | 2020-06-23 | Kala Pharmaceuticals, Inc. | Compositions and methods utilizing poly(vinyl alcohol) and/or other polymers that aid particle transport in mucus |
| JP6392209B2 (ja) | 2012-05-04 | 2018-09-19 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 粘液内層を通過する迅速な透過のための脂質ベース薬物キャリア |
| CA2885022A1 (en) | 2012-09-17 | 2014-03-20 | Bind Therapeutics, Inc. | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same |
| JP2015532928A (ja) | 2012-09-20 | 2015-11-16 | アキナ， インク．Ａｋｉｎａ， Ｉｎｃ． | 充填材料を含有する生体分解可能なマイクロカプセル |
| US9968603B2 (en) | 2013-03-14 | 2018-05-15 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
| EP2981248B1 (en) | 2013-04-01 | 2020-09-02 | Allergan, Inc. | Microsphere drug delivery system for sustained intraocular release |
-
2013
- 2013-05-06 JP JP2015510507A patent/JP6392209B2/ja active Active
- 2013-05-06 EP EP13722265.9A patent/EP2849728A1/en not_active Withdrawn
- 2013-05-06 HK HK15109178.8A patent/HK1208377A1/xx unknown
- 2013-05-06 WO PCT/US2013/039731 patent/WO2013166498A1/en not_active Ceased
- 2013-05-06 CA CA2872519A patent/CA2872519C/en active Active
- 2013-05-06 US US14/397,828 patent/US9889208B2/en active Active
- 2013-05-06 AU AU2013256008A patent/AU2013256008B2/en active Active
-
2017
- 2017-11-16 JP JP2017220782A patent/JP2018039836A/ja not_active Withdrawn
-
2018
- 2018-02-06 US US15/890,156 patent/US10556017B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015515992A5 (enExample) | ||
| US12409227B2 (en) | Cochleates made with soy phosphatidylserine | |
| JP2014532665A5 (enExample) | ||
| JP2018184470A5 (enExample) | ||
| JP2017515913A5 (enExample) | ||
| JP2015519383A5 (enExample) | ||
| EP3116479A1 (en) | Liposomal compositions for mucosal delivery | |
| WO2017019636A1 (en) | Compositions and methods for the treatment of sarcoidosis | |
| FI3954360T3 (fi) | Hiilihydraattien lääkevalmiste terapeuttiseen käyttöön | |
| ES2749192T3 (es) | Silibina para el tratamiento de las alteraciones oxidativas metabólicas en pacientes con esteatohepatitis no alcohólica (EHNA) | |
| CN112272555A (zh) | 用于治疗增殖性障碍的给药方案 | |
| CN110248666A (zh) | 甲钴胺素的鼻内用组合物 | |
| Terakosolphan et al. | Solubility of fluticasone propionate and beclomethasone dipropionate in simulated lung lining fluids | |
| JP5963973B2 (ja) | 最小閾値を超えるアルブミン、コレステロール及びｈｄｌの各レベルを有する患者の敗血症の治療方法 | |
| HK40044373A (en) | Dosing regimens for treatment of proliferative disorders | |
| NZ732995A (en) | Pharmaceutical combination comprising a biocompatible nanoparticle and a pharmaceutical compound, preparation and uses thereof | |
| HK1211181B (en) | Cochleates made with soy phosphatidylserine | |
| NZ732995B2 (en) | Pharmaceutical combination comprising a biocompatible nanoparticle and a pharmaceutical compound, preparation and uses thereof |